New exercise trick boosts strength in lung disease patients
NCT ID NCT07649850
First seen Jun 18, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This study tests whether adding a blood flow restriction cuff to aerobic exercise helps people with emphysema or COPD build muscle and improve daily function. Sixty participants will either do standard aerobic exercise or the same exercise with the cuff. The goal is to see if this low-intensity approach can safely enhance strength and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EMPHYSEMA OR COPD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aerobic exercise combined with blood flow restriction (BFR)
What this could lead to
If it works, this could offer a safer, more effective exercise program to help COPD patients build strength and move better.
What could go wrong
This is a small, early-stage trial (60 people) that hasn't started yet. Results may not apply to all COPD patients, and the benefits might be modest.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.